Comparative Pharmacology
Head-to-head clinical analysis: IQUIX versus NOROXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IQUIX versus NOROXIN.
IQUIX vs NOROXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
400 mg orally twice daily for 3-14 days depending on indication.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic